
# Colorado Immunization Manual



## **Colorado Immunization Manual Issued:** 9/1/98

**SUBJECT:** CONTENTS

**Revised:** 7/1/09

SECTION-PAGE: 7-1

**SECTION 7 Immunization Schedule** 

## **CONTENTS**

Summary of ACIP/AAP/AAFP Recommendations ......7-2

Recommended Adult Immunization Schedule......7-6

### 2009 Summary of ACIP/AAP/AAFP Recommended Immunization Schedule for Ages 0–6 Years

Colorado Department of Public Health and Environment/Colorado Clinical Guidelines Collaborative

### Current as of January 1, 2009. For updated information on pediatric immunizations, visit the CCGC website at www.coloradoguidelines.org or the CDPHE website at www.cdphe.state.co.us/dc/immunization.

Vaccine ▼ Age ►	Birth	1 month	2 months	4 months	6 months	12 months	15 months	18 months	19–23 months	2–3 years	4–6 years
Hepatitis B¹	НерВ	Не	pВ	See footnote 1	НерВ		НерВ				
Rotavirus <sup>2</sup>			RV	RV	RV <sup>2</sup>						
Diphtheria, Tetanus, Pertussis <sup>3</sup>			DTaP	DTaP	DTaP	See footnote 3	DT	аР			DTaP
Haemophilus influenzae type b⁴			Hib	Hib	Hib⁴	н	ib				
Pneumococcal⁵			PCV	PCV	PCV	PCV		PPSV			
Inactivated Poliovirus			IPV	IPV		IP	v				IPV
Influenza <sup>6</sup>						Influenza (Yearly)					
Measles, Mumps, Rubella <sup>7</sup>						MMR See footnote 7 MI			MMR		
Varicella <sup>8</sup>						Varicella See footnote 8		Varicella			
Hepatitis A <sup>9</sup>						HepA (2 doses) HepA Se			Series		
Meningococcal <sup>10</sup>										M	cv

Range of recommended ages

Certain high-risk groups

This schedule indicates the recommended ages for routine administration of currently licensed vaccines, as of December 1, 2008, for children aged 0 through 6 years. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. Licensed combination vaccines may be used whenever any component of the combination is indicated and other components are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the relevant Advisory Committee on Immunization Practices statement for detailed recommendations, including high-risk conditions: http://www.cdc.gov/vaccines/pubs/acip-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.

### - Footnotes -

### 1. Hepatitis B vaccine (HepB). (Minimum age: birth)

- At birth:

  - At birn: Administer monovalent HepB to all newborns before hospital discharge. If mother is hepatitis B surface antigen (HBsAg)-positive, administer HepB and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. If mother's HBsAg status is unknown, administer HepB within 12 hours of birth.
  - Determine mother's HBsAg status as soon as possible and, if HBsAg-positive, administer HBIG (no later than age 1 week).
  - After the birth dose:
  - The HepB series should be completed with either monovalent HepB or a combina-tion vaccine containing HepB. The second dose should be administered at age 1 or 2 months. The final dose should be administered no earlier than age 24 weeks.
  - Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg (anti-HBs) after completion of at least 3 doses of the HepB series, at age 9 through 18 months (generally at the next well-child visit).
  - 4-month dose:
- Administration of 4 doses of HepB to infants is permissible when combination vac-
- Administration of 4 doses of HepB to infants is permissible when combination vaccines containing HepB are administered after the birth dose.
   Rotavirus vaccine (RV). (*Minimum age: 6 weeks*)
   Administer the first dose at age 6 through 14 weeks (maximum age: 14 weeks 6 days). Vaccination should not be initiated for infants aged 15 weeks or older (i.e., 15 weeks 0 days or older).
  Administer the final dose in the series by age 8 months 0 days.
  If Rotarix<sup>®</sup> is administered at ages 2 and 4 months, a dose at 6 months is not indi-
- cated
- 3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP). (Mini-The fourth dose may be administered as early as age 12 months, provided at least
  - 6 months have elapsed since the third dose.
  - Administer the final dose in the series at age 4 through 6 years.
     Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age: 6

- Haemophilius Influenzae (ppc 2 compage)
  If PRP-OMP (PedvaxHIB® or Comvax® [HepB-Hib]) is administered at ages 2 and 4 months, a dose at age 6 months is not indicated.
  TriHiBit® (DTaP/Hib) should not be used for doses at ages 2, 4, or 6 months but can be used as the final dose in children aged 12 months or older.
  Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPSV])
  PCV is recommended for all children aged younger than 5 years. Administer 1 dose of PCV to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.

- Administer PPSV to children aged 2 years or older with certain underlying medical conditions (see *MMWR* 2000;49[No. RR-9]), including a cochlear implant.
   Influenza vaccine. (*Minimum age: 6 months for trivalent inactivated influenza*)
- vaccine [TIV]; 2 years for live, attenuated influenza vaccine [LAIV])
  Administer annually to children aged 6 months through 18 years.
  For healthy nonpregnant persons (i.e., those who do not have underlying medical conditions that predispose them to influenza complications) aged 2 through 49 years, either LAIV or TIV may be used. Children receiving TIV should receive 0.25 mL if aged 6 through 35 months or 0.5
- mL if aged 3 years or older.
- Administer 2 doses (separated by at least 4 weeks) to children aged younger than 9
- Administer 2 doses (separated by at least 4 weeks) to children aged younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received 1 dose.
   Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
   Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 28 days have elapsed since the first dose.
- the first dose
  - Varicella vaccine. (Minimum age: 12 months)
    Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 3 months have elapsed since the first dose.
- For children aged 12 months through 12 years the minimum interval between doses For children aged 12 months through 12 years the minimum interval between usses is 3 months. However, if the second dose was administered at least 28 days after the first dose, it can be accepted as valid.
  Hepatitis A vaccine (HepA). (Minimum age: 12 months)
  Administer to all children aged 1 year (i.e., aged 12 through 23 months). Administer
- Administer to all children aged right year (i.e., aged 12 through 25 months). Administer 2 doses at least 6 months age 1.
  Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
  HepA also is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006;55(No. RR-7).
- 10. Meningococcal vaccine. (Minimum age: 2 years for meningococcal conjugate
  - Administer MCVJ and for meningococcal polysacharide vaccine [MPSV])
     Administer MCV to children aged 2 through 10 years with terminal complement component deficiency, anatomic or functional asplenia, and certain other high-risk groups. See MMWR 2005;54(No. RR-7).
     Persons who received MPSV 3 or more years previously and who remain at
  - increased risk for meningococcal disease should be revaccinated with MCV.

7 - 2

### Catch-up immunization schedule for persons aged 4 months–6 years who start late or who are more than 1 month behind

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses.

Vaccine	Minimum age for Dose 1	Minimum interval between doses						
vaccine		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5			
Hepatitis B¹	Birth	4 weeks	<b>8 weeks</b> (and at least 16 weeks after first dose)					
Rotavirus <sup>2</sup>	6 weeks	4 weeks	4 weeks <sup>2</sup>					
Diphtheria, Tetanus, Pertussis³	6 weeks	4 weeks	4 weeks	6 months	6 months³			
Haemophilus influenzae type b <sup>4</sup>	6 weeks	4 weeks if first dose administered at younger than age 12 months 8 weeks (as final dose) if first dose administered at age 12–14 months No further doses needed if first dose administered at age 15 months or older	4 weeks <sup>4</sup> if current age is younger than 12 months 8 weeks (as final dose) <sup>4</sup> if current age is 12 months or older and second dose administered at younger than age 15 months No further doses needed if previous dose administered at age 15 months or older	8 weeks (as final dose) This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months				
Pneumococcal <sup>5</sup>	6 weeks	4 weeks if first dose administered at younger than age 12 months 8 weeks (as final dose for healthy children) if first dose administered at age 12 months or older or current age 24 through 59 months No further doses needed for healthy children if first dose administered at age 24 months or older	4 weeks if current age is younger than 12 months 8 weeks (as final dose for healthy children) if current age is 12 months or older No further doses needed for healthy children if previous dose administered at age 24 months or older	8 weeks (as final dose) This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months or for high-risk children who received 3 doses at any age				
Inactivated Poliovirus <sup>6</sup>	6 weeks	4 weeks	4 weeks	4 weeks <sup>6</sup>				
Measles, Mumps, Rubella <sup>7</sup>	12 months	4 weeks						
Varicella <sup>8</sup>	12 months	3 months						
Hepatitis A <sup>9</sup>	12 months	6 months						

### - Footnotes -

#### 1. Hepatitis B vaccine (HepB).

2

- Administer the 3-dose series to those not previously vaccinated.
  Rotavirus vaccine (RV).
  The maximum age for the first dose is 14 weeks 6 days. Vaccination should not be
- initiated for infants aged 15 weeks or older (i.e., 15 weeks 0 days or older).
  Administer the final dose in the series by age 8 months 0 days.
  If Rotarix<sup>®</sup> was administered for the first and second doses, a third dose is not indi-
- cated.
- Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).
   The fifth dose is not necessary if the fourth dose was administered at age 4 years or older.

4.

- Haemophilus influenzae type b conjugate vaccine (Hib).
  Hib vaccine is not generally recommended for persons aged 5 years or older. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults. However, studies suggest good immunogenicity in persons who have sickle cell disease, leukemia, or HIV infection, or who have had a splenectomy; administering 1 dose of Hib vaccine to these persons is not contraindicated. not contraindicated.
- If the first 2 doses were PRP-OMP (PedvaxHIB® or Comvax®), and administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose.
   If the first dose was administered at age 7 through 11 months, administer 2 doses approach by 4 weeks after the 12 through 15 months and at least 8 weeks after the second dose.
- separated by 4 weeks and a final dose at age 12 through 15 months.

#### Pneumococcal vaccine. 5.

Administer 1 dose of pneumococcal conjugate vaccine (PCV) to all healthy children aged 24 through 59 months who have not received at least 1 dose of PCV on or after age 12 months.

- · For children aged 24 through 59 months with underlying medical conditions, administer 1 dose of PCV if 3 doses were received previously or administer 2 doses of
- PCV at least 8 weeks apart if fewer than 3 doses were received previously. Administer pneumococcal polysaccharide vaccine (PPSV) to children aged 2 years or older with certain underlying medical conditions (see MMWR 2000;49[No. RR-9), including a cochlear implant, at least 8 weeks after the last dose of PCV.
  6. Inactivated poliovirus vaccine (IPV).
  • For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age 4 years or older.
  • If both OPV and IPV were administered as part of a series, a total of 4 doses should be oblide activated received are abilities abilities.

7.

In both OF v and IF v were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.
Measles, mumps, and rubella vaccine (MMR).
Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 28 days have elapsed since the dose. the first dose

. If not previously vaccinated, administer 2 doses with at least 28 days between doses

- 8. Varicella vaccine.
  - Administer the second dose at age 4 through 6 years. However, the second dose may be administered before age 4, provided at least 3 months have elapsed since the first dose.
  - For persons aged 12 months through 12 years, the minimum interval between doses is 3 months. However, if the second dose was administered at least 28 days after the first dose, it can be accepted as valid.
- 9.
- Hepatitis A vaccine (HepA).
  HepA is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006;55(No. RR-7).

### 2009 Summary of ACIP/AAP/AAFP Recommended Immunization Schedule for Ages 7–18 Years

Colorado Department of Public Health and Environment/Colorado Clinical Guidelines Collaborative

### Current as of January 1, 2009. For updated information on pediatric immunizations, visit the CCGC website at www.coloradoguidelines.org or the CDPHE website at www.cdphe.state.co.us/dc/immunization.

Vaccine ▼ Age ►	7–10 years	11–12 YEARS	13–18 years
Diphtheria, Tetanus, Pertussis <sup>1</sup>	See footnote 1	Tdap	Tdap
Human Papillomavirus <sup>2</sup>	See footnote 2	HPV (3 doses)	HPV Series
Meningococcal <sup>3</sup>	MCV	MCV	MCV
Influenza <sup>4</sup>		Influenza (Yearly)	
Pneumococcal⁵		PPSV	
Hepatitis A <sup>6</sup>		HepA Series	
Hepatitis B <sup>7</sup>		HepB Series	
Inactivated Poliovirus <sup>8</sup>		IPV Series	
Measles, Mumps, Rubella <sup>9</sup>		MMR Series	
Varicella <sup>10</sup>		Varicella Series	

Range of recommended ages

Catch-up immunization

Certain high-risk groups

This schedule indicates the recommended ages for routine administration of currently licensed vaccines, as of December 1, 2008, In schedule indicates the recommended ages for routine administration of currently licensed vaccines, as of December 1, 2008, for children aged 7 through 18 years. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. Licensed combination vaccines may be used whenever any component of the combination is indicated and other components are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the relevant Advisory Committee on Immunization Practices statement for detailed recommendations, including high-risk conditions: http://www.cdc.gov/vaccines/pubs/acip-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.

### Footnotes

- Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Mini-mum age: 10 years for BOOSTRIX® and 11 years for ADACEL®) Administer at age 11 or 12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diph
  - theria toxoid (Td) booster dose.
  - Persons aged 13 through 18 years who have not received Tdap should receive a dose A 5-year interval from the last Td dose is encouraged when Tdap is used as a
  - booster dose; however, a shorter interval may be used if pertussis immunity is needed.

### 2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)

- Administer the first dose to females at age 11 or 12 years.
  Administer the second dose 2 months after the first dose and the third dose 6
- months after the first dose (at least 24 weeks after the first dose). Administer the series to females at age 13 through 18 years if not previously vacci-
- nated. 3. Meningococcal conjugate vaccine (MCV).
  - Administer at age 11 or 12 years, or at age 13 through 18 years if not previously vaccinated.

  - vaccinated.
    Administer to previously unvaccinated college freshmen living in a dormitory.
    MCV is recommended for children aged 2 through 10 years with terminal complement component deficiency, anatomic or functional asplenia, and certain other groups at high risk. See *MMWR* 2005;54(No. RR-7).
    Persons who received MPSV 5 or more years previously and remain at increased risk for meningococcal disease should be revaccinated with MCV.
- 4. Influenza vaccine.
  - Administer annually to children aged 6 months through 18 years. For healthy nonpregnant persons (i.e., those who do not have underlying medical conditions that predispose them to influenza complications) aged 2 through 49 years, either LAIV or TIV may be used. Administer 2 doses (separated by at least 4 weeks) to children aged younger than 9
  - years who are receiving influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received 1 dose.

- 5. Pneumococcal polysaccharide vaccine (PPSV). Administer to children with certain underlying medical conditions (see MMWR 1997;46[No. RR-8]), including a cochlear implant. A single revaccination should be administered to children with functional or anatomic asplenia or other immunocomadministered to children with failed and a promising condition after 5 years.
  Hepatitis A vaccine (HepA).
  Administer 2 doses at least 6 months apart.
- HepA is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006:55(No. RR-7).

#### 7. Hepatitis B vaccine (HepB).

- Administer the 3-dose series to those not previously vaccinated.
  A 2-dose series (separated by at least 4 months) of adult formulation Recombivax HB® is licensed for children aged 11 through 15 years.
  8. Inactivated poliovirus vaccine (IPV).
  For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth
- - dose is not necessary if the third dose was administered at age 4 years or older.
    If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.

#### Measles, mumps, and rubella vaccine (MMR).

If not previously vaccinated, administer 2 doses or the second dose for those who have received only 1 dose, with at least 28 days between doses.

- 10. Varicella vaccine.
  - For persons aged 7 through 18 years without evidence of immunity (see MMWR 2007;56[No. RR-4]), administer 2 doses if not previously vaccinated or the second
  - For persons aged 7 through 12 years, the minimum interval between doses is 3 months. However, if the second dose was administered at least 28 days after the first dose, it can be accepted as valid.
  - For persons aged 13 years and older, the minimum interval between doses is 28 davs.

### Catch-up immunization schedule for persons aged 7–18 years who start late or who are more than 1 month behind

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses.

Vaccine	Minimum age for Dose 1	Minimum interval between doses						
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dose 5			
Tetanus, Diphtheria/Tetanus, Diphtheria, Pertussis <sup>1</sup>	7 years <sup>1</sup>	4 weeks	4 weeks if first dose administered at younger than age 12 months 6 months if first dose administered at age 12 months or older	<b>6 months</b> if first dose administered at younger than age 12 months				
Human Papillomavirus²	9 years	Routine dosing intervals are recommended <sup>2</sup>						
Hepatitis A <sup>3</sup>	12 months	6 months						
Hepatitis B <sup>4</sup>	Birth	4 weeks	<b>8 weeks</b> (and at least 16 weeks after first dose)					
Inactivated Poliovirus <sup>5</sup>	6 weeks	4 weeks	4 weeks	4 weeks⁵				
Measles, Mumps, Rubella <sup>6</sup>	12 months	4 weeks						
Varicella <sup>7</sup>	12 months	3 months if the person is younger than age 13 years 4 weeks if the person is aged 13 years or older						

### Footnotes

- 1. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids
- Tetarius and diprimeria toxolds vaccine (Td) and tetarius and diprimeria toxolds and acellular pertussis vaccine (Tdap).
   Doses of DTaP are counted as part of the Td/Tdap series
   Tdap should be substituted for a single dose of Td in the catch-up series or as a booster for children aged 10 through 18 years; use Td for other doses.
   Human papillomavirus vaccine (HPV).
   Administer the series to females at age 13 through 18 years if not previously vaccine (HPV).
- nated.
  - Use recommended routine dosing intervals for series catch-up (i.e., the second and third doses should be administered at 2 and 6 months after the first dose). However, the minimum interval between the first and second doses is 4 weeks. The mini-mum interval between the second and third doses is 12 weeks, and the third dose should be given at least 24 weeks after the first dose.
- Hepatitis A vaccine (HepA).
   HepA is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006;55(No. RR-7).

#### 4. Hepatitis B vaccine (HepB).

- Administer the 3-dose series to those not previously vaccinated.
  A 2-dose series (separated by at least 4 months) of adult formulation Recombivax HB<sup>®</sup> is licensed for children aged 11 through 15 years.
- 5. Inactivated poliovirus vaccine (IPV).
   For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age 4 years or older.
- If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.
  6. Measles, mumps, and rubella vaccine (MMR).
- - If not previously vaccinated, administer 2 doses with at least 28 days between doses
- 7. Varicella vaccine.
  - For persons aged 12 months through 12 years, the minimum interval between doses is 3 months. However, if the second dose was administered at least 28 days after the first dose, it can be accepted as valid.
  - . For persons aged 13 years and older, the minimum interval between doses is 28 davs.

### Immunization Program Resources



Colorado Department

of Public Health

and Environment

General Immunization Questions: (303) 692-2650 Vaccine Orders: (303) 692-2795 Vaccines for Children (VFC) Program: (719) 545-4650 x22, 1-866-530-1813 Hepatitis B Project: (303) 692-2673 Disease Reports: 1-800-866-2759 Vaccine Adverse Event Reporting System (VAERS): (970) 323-6056, 1-866-896-1586. Clinically significant adverse events that follow immunization should be reported to VAERS. Guidance about how to

obtain and complete a VAERS form is also available at http://www.vaers.hhs.gov.

### Vaccine Information Statements (VISs):

http://www.cdc.gov/vaccines/pubs/vis

Family Healthline (Parent Information): (303) 692-2229 (Denver metro area) or 1-800-688-7777

CDC Information Contact Center (for immunization guestions): 1-800-CDC-INFO (1-800-232-4636); NIPINFO@cdc.gov



### Background

The Colorado Clinical **Guidelines Collaborative** was formed in 1996 to address the challenges for the use and implementation of clinical guidelines across health care systems in Colorado. Current membership represents 50 health care organizations.



CCGC is a Colorado coalition of healthcare stakeholders (health plans, physicians, hospitals, employers, government agencies, quality improvement organizations and other entities) working collaboratively to implement systems and processes, using evidenced-based clinical guidelines to improve healthcare outcomes in Colorado.

The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/vaccines/recs/acip), the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org). 7 - 5

### October 2008–September 2009 Summary of ACIP/ACOG/AAFP Adult Immunization Recommendations

Colorado Department of Public Health and Environment/Colorado Clinical Guidelines Collaborative

### Fig. 1: Recommended Adult Immunization Schedule, by Vaccine and Age Group

Vaccine ▼ Age group ►	19–26 years	27–49 years	50–59 years	60–64 years ≥65 years		
Tetanus, diphtheria, pertussis (Td/Tdap) <sup>1,*</sup>	Substitute 1-ti	Td booster every 10 yrs				
Human papillomavirus (HPV) <sup>2,*</sup>	3 doses (females)					
Varicella <sup>3,*</sup>			2 doses	1		
Zoster <sup>4</sup>				1 d	ose	
Measles, mumps, rubella (MMR) <sup>5,*</sup>	1 or 2 dos	es	1	1 dose		
Influenza <sup>6,*</sup>				I dose annually		
Pneumococcal (polysaccharide) <sup>7,8</sup>		1 or 2	doses		1 dose	
Hepatitis A <sup>9,*</sup>			2 doses			
Hepatitis B <sup>10,*</sup>			3 doses			
Meningococcal <sup>11,*</sup>			1 or more doses			

These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of January 1, 2009. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory Committee on Immunization Practices (http://www.cdc.gov/vaccines/pubs/acip-list.htm).

Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.

Information on how to file a Vaccine Injury Compensation Program claim is available at http://www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.

Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at http://www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 24 hours a day, 7 days a week.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

### Fig. 2: Vaccines That Might Be Indicated for Adults Based on Medical and Other Indications

Indication ► Vaccine ▼	Pregnancy	Immunocompromis- ing conditions (excluding human immunodeficiency virus [HIV]) <sup>13</sup>	CD4+ T	tion <sup>3,12,13</sup> lympho- count ≥200 cells/µL	Diabetes, heart disease, chronic lung disease, chronic alco- holism	Asplenia <sup>12</sup> (includ- ing elective splenectomy and terminal comple- ment component deficiencies)	Chronic liver disease	Kidney fail- ure, end- stage renal disease, receipt of hemodialysis	Health-care personnel
Tetanus, diphtheria, pertussis (Td/Tdap) <sup>1,*</sup>	Td	s	l Substitute	: 1-time dos :	e of Tdap for To	l d booster; then boos l	t with Td eve	ry 10 yrs	
Human papillomavirus (HPV) <sup>2,*</sup>				: 3 c	loses for female	es through age 26 ye	ars	1	
Varicella <sup>3,*</sup>		Contraindicated				2 dos	es	1	
Zoster <sup>4</sup>		Contraindicated				1	1 dose	1	
Measles, mumps, rubella (MMR) <sup>5,*</sup>		Contraindicated				1 or 2 do	i oses		
Influenza <sup>6,*</sup>		1		: 1 dos :	e TIV annually	1	1		1 dose TIV or LAIV annually
Pneumococcal (polysaccharide) <sup>7,8</sup>				:	1 or 2 dose	) 95	1	1	
Hepatitis A <sup>9,*</sup>			2 0	loses :					
Hepatitis B <sup>10,*</sup>					3	doses			
Meningococcal <sup>11,*</sup>		1 or mo	ore doses	:				1	

NOTE: These schedules must be read along with the footnotes. \*Covered by the Vaccine Injury Compensation Program.

For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection) Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications) Contraindicated

For updates on vaccines, visit the CCGC website at www.coloradoguidelines.org or the CDPHE website at www.cdphe.state.co.us/dc/immunization.

### FOOTNOTES

Measles component: Adults born before 1957 generally are considered immune to measles. Adults born during or after 1957 should receive 1

or more doses of MMR unless they have a medical contraindication, documentation of 1 or more doses, history of measles based on

A second dose of MMR is recommended for adults who 1) have been A second dose of MMK is recommended for adults who 1) have been recently exposed to measles or are in an outbreak setting; 2) have been vaccinated with an unknown type of measles vaccine; 3) have been vaccinated with an unknown type of measles vaccine during 1963–1967; 4) are students in postsecondary educational institutions; 5) work in a health-care facility; or 6) plan to travel internationally.

Mumps component: Adults born before 1957 generally are considered immune to mumps. Adults born during or after 1957 should receive 1 dose of MMR unless they have a medical contraindication, history of

mumps based on health-care provider diagnosis, or laboratory evi-

A second dose of MMR is recommended for adults who 1) live in a community experiencing a mumps outbreak and are in an affected age

group; 2) are students in postsecondary educational institutions; 3)

work in a health-care facility; or 4) plan to travel internationally. For unvaccinated health-care personnel born before 1957 who do not have

other evidence of mumps immunity, administering 1 dose on a routine basis should be considered and administering a second dose during an outbreak should be strongly considered.

Rubella component: 1 dose of MMR vaccine is recommended for

women whose rubella vaccination history is unreliable or who lack lab-oratory evidence of immunity. For women of childbearing age, regard-less of birth year, rubella immunity should be determined and women

should be counseled regarding congenital rubella syndrome. Women who do not have evidence of immunity should receive MMR vaccine

upon completion or termination of pregnancy and before discharge

Medical indications: Chronic disorders of the cardiovascular or pul-

monary systems, including asthma; chronic metabolic diseases, including diabetes mellitus, renal or hepatic dysfunction, hemoglo-binopathies, or immunocompromising conditions (including immuno-compromising conditions caused by medications or human immunode-

compromising conductors caused by medications or numan immunode-ficiency virus [HIV]); any condition that compromises respiratory function or the handling of respiratory secretions or that can increase the risk of aspiration (e.g., cognitive dysfunction, spinal cord injury, or seizure disorder or other neuromuscular disorder); and pregnancy dur-ing the influenza season. No data exist on the risk for severe or com-

plicated influenza disease among persons with asplenia; however, influenza is a risk factor for secondary bacterial infections that can cause severe disease among persons with asplenia.

Occupational indications: All health-care personnel, including those

employed by long-term care and assisted-living facilities, and care-givers of children less than 5 years old.

Other indications: Residents of nursing homes and other long-term

care and assisted-living facilities; persons likely to transmit influenza to

persons at high risk (e.g., in-home household contacts and caregivers of children aged less than 5 years old, persons 65 years old and older

and persons of all ages with high-risk condition(s); and anyone who would like to decrease their risk of getting influenza. Healthy, nonpreg-nant adults aged less than 50 years without high-risk medical condi-

tions who are not contacts of severely immunocompromised persons in special care units can receive either intranasally administered live, attenuated influenza vaccine (FluMist®) or inactivated vaccine. Other

functional control and the series of the ser

Other indications: Residents of nursing homes or other long-term care

facilities and persons who smoke cigarettes. Routine use of PPSV is not recommended for Alaska Native or American Indian persons

younger than 65 years unless they have underlying medical conditions that are PPSV indications. However, public health authorities may consider recommending PPSV for Alaska Natives and American Indians aged 50 through 64 years who are living in areas in which the risk of

One-time revaccination after 5 years is recommended for persons with

chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); and for persons with immunocompromising conditions. For persons aged 65 years and older,

persons should receive the inactivated vaccine. 7. Pneumococcal polysaccharide (PPSV) vaccination Medical indications: Chronic lung disease (including asthma); chronic cardiovascular diseases; diabetes mellitus; chronic liver diseases, cir-

invasive pneumococcal disease is increased.

8. Revaccination with PPSV

health-care provider diagnosis, or laboratory evidence of immunity.

nated unless their condition constitutes a contraindication

5. Measles, mumps, rubella (MMR) vaccination

dence of immunity.

from the health-care facility.

6. Influenza vaccination

#### 1. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination

Tdap should replace a single dose of Td for adults aged 19 through 64 years who have not received a dose of Tdap previously Adults with uncertain or incomplete history of primary vaccination

series with tetanus and diphtheria toxoid-containing vaccines should begin or complete a primary vaccination series. A primary series for adults is 3 doses of tetanus and diphtheria toxoid-containing vaccines; administer the first 2 doses at least 4 weeks apart and the third dose 6–12 months after the second. However, Tdap can substitute for any one of the doses of Td in the 3-dose primary series. The booster dose of tetanus and diphtheria toxoid-containing vaccine should be administered to adults who have completed a primary series and if the last vac-cination was received 10 or more years previously. Tdap or Td vaccine may be used, as indicated.

If a woman is pregnant and received the last Td vaccination 10 or more years previously, administer Td during the second or third trimester. If the woman received the last Td vaccination less than 10 years previously. administer Tdap during the immediate postpartum period. A dose of Tdap is recommended for postpartum women, close contacts of infants aged less than 12 months, and all health-care personnel with direct patient contact if they have not previously received Tdap. An interval as short as 2 years from the last Td is suggested; shorter intervals can be used. Td may be deferred during pregnancy and Tdap substituted in the immediate postpartum period, or Tdap may be administered instead of Td to a pregnant woman after an informed discussion with the woman.

Consult the ACIP statement for recommendations for administering Td as prophylaxis in wound management.

#### 2. Human papillomavirus (HPV) vaccination

HPV vaccination is recommended for all females aged 11 through 26 years (and may begin at age 9 years) who have not completed the vac-cine series. History of genital warts, abnormal Papanicolaou test, or pos-tive HPV DNA test is not evidence of prior infection with all vaccine HPV types; HPV vaccination is recommended for persons with such histories.

Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, females who are sexually active should still be vaccinated consistent with age-based recommenda-tions. Sexually active females who have not been infected with any of the four HPV vaccine types receive the full benefit of the vaccination. Vaccination is less beneficial for females who have already been infected with one or more of the HPV vaccine types.

A complete series consists of 3 doses. The second dose should be administered 2 months after the first dose; the third dose should be administered 6 months after the first dose.

HPV vaccination is not specifically recommended for females with the HPV vaccination is not specifically recommended in the medical indications described in Figure 2, "Vaccines that might be indi-cated for adults based on medical and other indications." Because HPV vaccine is not a live-virus vaccine, it may be administered to per-sons with the medical indications described in Figure 2. However, the immune response and vaccine efficacy might be less for persons with the medical indications described in Figure 2 than in persons who do be they be medical indications described an event on the medical indications described and event on the medical indications described in Figure 2. not have the medical indications described or who are immunocompe-tent. Health-care personnel are not at increased risk because of occu-pational exposure, and should be vaccinated consistent with agebased recommendations

#### 3. Varicella vaccination

All adults without evidence of immunity to varicella should receive 2 doses of single-antigen varicella vaccine if not previously vaccinated or the second dose if they have received only one dose, unless they have a medical contraindication. Special consideration should be given to those who 1) have close contact with persons at high risk for severe those who 1) have close contact with persons at high risk for severe disease (e.g., health-care personnel and family contacts of persons with immunocompromising conditions) or 2) are at high risk for expo-sure or transmission (e.g., teachers; child care employees; residents and staff members of institutional settings, including correctional insti-tutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers).

Evidence of immunity to varicella in adults includes any of the follow-ing: 1) documentation of 2 doese of varicella vaccine at least 4 weeks apart; 2) U.S.-born before 1980 (although for health-care personnel and pregnant women, birth before 1980 should not be considered evi-dence of immunity); 3) history of varicella based on diagnosis or verifi-cation of varicella by a health-care provider (for a patient reporting a history of or presenting with an atypical case, a mild case, or both, health-care providers should seek either an epidemiologic link to a typ-icel varicella case or to a laboratory confirmed case or a varicence of im-(a) varicella case or to a laboratory-confirmed case or evidence of lab-oratory confirmation, if it was performed at the time of acute disease); 4) history of herpes zoster based on health-care provider diagnosis or evidence of immunity or laboratory confirmation of disease.

Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of preg-nancy and before discharge from the health-care facility. The second dose should be administered 4–8 weeks after the first dose.

#### 4. Herpes zoster vaccination

#### herpes zoster. Persons with chronic medical conditions may be vacci- 9. Hepatitis A vaccination

Medical indications: Persons with chronic liver disease and persons who receive clotting factor concentrates

Behavioral indications: Men who have sex with men and persons who use illegal drugs.

Occupational indications: Persons working with hepatitis A virus (HAV) infected primates or with HAV in a research laboratory setting.

Other indications: Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A (a list of countries is available at http://wwwn.cdc.gov/travel/contentdiseases.aspx) and any person seeking protection from HAV infection.

Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6-12 months (Havrix®), or 0 and 6-18 months (Vaqta®). If the combined hepatitis A and hepatitis B vaccine (Twinrix®) is used, administer 3 doses at 0, 1, and 6 months; alterna-tively, a 4-dose schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.

#### 10. Hepatitis B vaccination

Medical indications: Persons with end-stage renal disease, including patients receiving hemodialysis; persons with HIV infection; and persons with chronic liver disease.

Occupational indications: Health-care personnel and public-safety work-ers who are exposed to blood or other potentially infectious body fluids.

Behavioral indications: Sexually active persons who are not in a longterm, mutually monogamous relationship (e.g., persons with more than 1 sex partner during the previous 6 months); persons seeking evalua-tion or treatment for a sexually transmitted disease (STD); current or recent injection-drug users; and men who have sex with men.

Other indications: Household contacts and sex partners of persons with chronic hepatitis B virus (HBV) infection; clients and staff members of institutions for persons with developmental disabilities; international travelers to countries with high or intermediate prevalence of chronic HBV infection (a list of countries is available at http://wwwn.cdc.gov/travel/contentdiseases.aspx); and any adult seeking protection from HBV infection.

e-settings: STD treatment facilities; HIV testing and treatment facilities; facilities providing drug-abuse treatment and prevention services; health-care settings targeting services to injection-drug users or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients; and institutions and nonresidential daycare facilities for persons with develop mental disabilities.

If the combined hepatitis A and hepatitis B vaccine (Twinrix®) is used administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule, administered on days 0, 7, and 21 to 30 followed by a booster dose at month 12 may be used.

Special formulation indications: For adult patients receiving hemodialysis or with other immunocompromising conditions, 1 dose of 40  $\mu$ g/mL (Recombivax HB<sup>®</sup>) administered on a 3-dose schedule or 2 doses of 20 µg/mL (Engerix-B®) administered simultaneously on a 4-dose schedule at 0,1, 2 and 6 months.

#### 11. Meningococcal vaccination

Medical indications: Adults with anatomic or functional asplenia, or terminal complement component deficiencies.

Other indications: First-year college students living in dormitories; microbiologists routinely exposed to isolates of Neisseria meningitidis; military recruits; and persons who travel to or live in countries in which miniary recurus, and persons who travel to or live in countries in which meningococal disease is hyperendemic or epidemic (e.g., the "menin-gitis belt" of sub-Saharan Africa during the dry season [Decem-ber-June]), particularly if their contact with local populations will be prolonged. Vaccination is required by the government of Saudi Arabia for all travelers to Mecca during the annual Hajj.

Meningococcal conjugate vaccine (MCV) is preferred for adults with any of the preceding indications who are aged 55 years or younger, although meningococcal polysaccharide vaccine (MPSV) is an accept-able alternative. Revaccination with MCV after 5 years might be indi-cated for adults previously vaccinated with MPSV who remain at increased risk for infection (e.g., persons residing in areas in which dis-teres inertiated. ease is epidemic).

#### 12. Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used

Hib vaccine generally is not recommended for persons aged 5 years and older. No efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults. However, studies suggest good immunogenicity in patients who have sickle cell disease, leukemia, or HIV infection or who have had a splenectomy; administering 1 dose of vaccine to these patients is not contraindicated.

#### 13. Immunocompromising conditions

Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, and influenza [trivalent inactivated influenza vaccine]) and live vaccines generally are avoided in persons with immune def-ciencies or immunocompromising conditions. Information on specific conditions is available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.

A single dose of zoster vaccine is recommended for adults aged 60 years and older regardless of whether they report a prior episode of

# Immunization Program Resources



Colorado Department

of Public Health

and Environment

**General Immunization Questions:** (303) 692-2650

Website: www.cdphe.state.co.us/dc/ immunization

CIPAC Website: (with flu shot clinic listings) www.immunizecolorado.com

Hepatitis B Project: (303) 692-2673 Disease Reports: 1-800-866-2759 Vaccine Information Statements (VISs):

www.cdc.gov/vaccines/pubs/vis

Family Healthline: (303) 692-2229 (Denver metro) or 1-800-688-7777 CDC Information Contact Center (for immunization questions): 1-800-CDC-INFO (1-800-232-4636); NIPINFO@cdc.gov



#### Background

The Colorado Clinical Guidelines Collaborative was formed in 1996 to address the challenges for the use and implementation of clinical quidelines across health care systems in Colorado. Current membership represents 50 health care organizations.

### **Mission Statement**

CCGC is a Colorado coalition of healthcare stakeholders (health plans, physicians, hospitals, employers, government agencies, quality improvement organizations and other entities) working collaboratively to implement systems and processes, using evidenced-based clinical guidelines to improve healthcare outcomes in Colorado.



DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION

Website: www.cdc.gov/vaccines

Approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the American College of Physicians. Complete statements from ACIP are available at http://www.cdc.gov/vaccines/pubs/acip-list.htm.

In one-time revaccination if they were vaccinated 5 or more years previous ly and were aged less than 65 years at the time of primary vaccination.